ℹ️
🇬🇧
Search
Search for publications relevant for "disease-modifying effect"
disease-modifying effect
Publication
Class
Person
Publication
Programmes
Export current view
publication
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
2022 |
First Faculty of Medicine
publication
Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS
2019 |
First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 2021
2023 |
First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.
2009 |
First Faculty of Medicine
publication
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
2017 |
First Faculty of Medicine
publication
Disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis
2005 |
First Faculty of Medicine
publication
Sex-specific disease modifiers in juvenile myoclonic epilepsy
2022 |
Second Faculty of Medicine
publication
Disease-modifying treatment approaches in Huntington disease: Past and future
2022 |
First Faculty of Medicine
publication
Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
2012 |
First Faculty of Medicine
publication
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
2022 |
First Faculty of Medicine
publication
Therapy of rheumatoid arthritis with synthetic and biological disease modifying drugs.
2009 |
First Faculty of Medicine
publication
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
2021 |
First Faculty of Medicine
publication
Design, synthesis, and biological evaluation of 1-benzylamino-2-hydroxyalkyl derivatives as new potential disease-modifying multifunctional anti-Alzheimer's agents
2018 |
Publication without faculty affiliation
publication
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study
2019 |
First Faculty of Medicine
publication
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination
2022 |
First Faculty of Medicine
publication
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
2019 |
First Faculty of Medicine
publication
Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment
2014 |
First Faculty of Medicine
publication
Adverse Events of Drugs Used in Therapy or Rheumatic diseases - I. Disease Modifying drugs Used in the Therapy of Rheumatoid Arthritis and Basic Principals of Monitoring of Safety
2003 |
First Faculty of Medicine
publication
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
2016 |
First Faculty of Medicine
publication
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
2019 |
First Faculty of Medicine
publication
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010 |
First Faculty of Medicine
publication
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
2023 |
First Faculty of Medicine
publication
Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration
2018 |
First Faculty of Medicine
publication
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
2010 |
First Faculty of Medicine
publication
Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis
2007 |
First Faculty of Medicine
publication
Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis
2007 |
Faculty of Physical Education and Sport
publication
Multiple sclerosis - early diagnosis and treatment options
2019 |
First Faculty of Medicine
publication
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
2012 |
First Faculty of Medicine
publication
Prevention of surgical Joint Replacement in the Long-term follow-up of Recent Disease-modifying Drug Trials in Osteoarthritis
Publication without faculty affiliation
publication
Multiple sclerosis
2008 |
First Faculty of Medicine